Compound Clopidol Premix Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is the synthetic pyridinol coccidiostat 3,5-dichloro-2,6-dimethylpyridin-4-ol, CAS 2971-90-6, with molecular formula C7H7Cl2NO and relative molecular mass 192.04. The term “compound” in this designation identifies the chemical class, not a multi-active admixture; the item is an unformulated veterinary-grade active substance rather than a finished diluted feed premix. The powder is a white to off-white crystalline solid with pH-dependent solubility: practically insoluble in neutral aqueous media, soluble in dilute mineral acids and in selected polar organic solvents. That solubility profile determines whether the API is processed into a single-phase solution or dispersed as a suspension. The material is controlled for assay, related substances, loss on drying, sulphated ash, and residual solvent content. Storage is specified in tightly closed HDPE drums with LDPE liners at or below 30°C and relative humidity below 60% to avoid moisture-mediated caking. The API is produced under quality requirements aligned with ICH Q7 for active pharmaceutical ingredients, and analytical data are generated under ISO/IEC 17025 controlled methods.

Two physical grades are commonly specified for downstream processing. The fine-milled grade is used when content uniformity in low-dose tablets is the limiting parameter; the regular-milled grade is used for premix and granule operations where dust control and carrier adhesion dominate. Particle-size distribution is determined by laser diffraction in accordance with ISO 13320:2020. For fine-milled material, a d(0.9) upper limit of 60 µm is often negotiated with the manufacturer to support single-tablet content uniformity; for regular-milled premix material, coarse agglomerates above 250 µm are removed. Published compendial particle-size monographs for clopidol are limited, so the certificate of analysis and the supplier’s validated method are the normative references.

What Differentiates Clopidol from Ionophore and Antithiamine Coccidiostats?

Clopidol differs chemically and mechanistically from the ionophore class represented by monensin, salinomycin, and narasin. Ionophores are fermentation-derived polyether compounds that modify ion flux across parasite membranes; clopidol is a fully synthetic pyridinol that interferes with early coccidial development and has no ionophoric activity. Compared with amprolium hydrochloride, a thiamine analogue, clopidol does not act by competitive inhibition of thiamine transport in Eimeria; therefore, cross-resistance to amprolium is not inherent. In field-use programs, clopidol is positioned in shuttle or rotation schedules because continuous exposure has been associated with reduced sensitivity in Eimeria tenella populations. The product’s anticoccidial spectrum covers Eimeria tenella, Eimeria necatrix, Eimeria acervulina, Eimeria maxima, and Eimeria brunetti in chickens when incorporated into complete feed within accepted inclusion ranges. The typical in-feed active concentration is 125 to 250 mg/kg complete feed, achieved by dilution of the API into a calcium carbonate or lactose carrier. Regulatory residual limits vary; when the product is used in food-producing birds, the withdrawal period and maximum residue limit must be confirmed against the regional veterinary medicinal product authorization and Commission Regulation (EU) No 37/2010 where applicable.

Processing Envelope for Tablet, Capsule, and Granule Forms

Tablet and capsule manufacture from clopidol API depends on particle-size distribution, bulk density, and flow. The crystalline powder is screened to remove agglomerates above 250 µm through a stainless-steel oscillating granulator before blending; cohesive flow can occur at low moisture, so loss on drying is controlled to ≤ 0.5%. Direct compression and capsule filling generally require a flowable diluent matrix of microcrystalline cellulose and lactose monohydrate, but published compression-force transfer data for clopidol-containing tablets are limited. Content uniformity is evaluated in accordance with Ph. Eur. 2.9.40, and blend homogeneity is expected to achieve relative standard deviation not more than 5.0% before compression. Dry granulation by roller compaction is preferred when drug loading exceeds 40% w/w, because wet granulation with neutral aqueous binder can produce non-uniform API distribution as a result of the free base’s low aqueous solubility. Tablet friability is measured by Ph. Eur. 2.9.7, and disintegration is checked according to Ph. Eur. 2.9.1 for immediate-release tablets. Capsule filling on dosing-disc or tamping-pin equipment should be qualified with in-process mass variability checks at least every 30 minutes. Hardware and processing limits should be derived from batch-scale trials because particle-size distribution varies between API vendors.

For powders and granules intended for oral administration or in-feed use, fluid-bed top-spray granulation is employed with a binder solution of povidone or hydroxypropyl cellulose. The critical process parameters are inlet air temperature, atomizing pressure, and product moisture. A product temperature range of 35°C to 45°C with a control tolerance of ±5°C is commonly applied for aqueous binder systems at 8% w/w spray rate; excursions above 50°C can produce hard agglomerates, while temperatures below 30°C give uneven wetting and broad granule size. Final granule moisture is controlled to ≤ 2.0% w/w, and granule size is restricted to 150–710 µm for feed dilution. If a solution dosage form is required, the pH is adjusted into the acidic range below 4.0, and the vehicle’s dielectric constant is raised with propylene glycol or glycofurol; however, published solubility data for clopidol in mixed solvent systems are limited. Powder blends for direct dosing must not be considered interchangeable with feed premixes because the carrier system and particle-size design differ.

Injectable clopidol products are constrained by the API’s practically insoluble neutral aqueous solubility. A true solution for injection would require pH reduction with pharmaceutically acceptable acids or the addition of co-solvents such as propylene glycol or glycofurol; however, published toxicological and stability data for clopidol injectables in target species are limited, and veterinary pharmacopoeial monographs for injectable clopidol are not available. Because of this data gap, formulators cannot assume that an injectable product is bioequivalent to approved oral feed premises without residue and pharmacokinetic studies. If a suspension injection is developed, particle-size distribution should be controlled by laser diffraction in accordance with ISO 13320:2020, and syringeability should be verified with a needle diameter of 21 G or wider using ISO 7886-1:2017-compliant syringes. Terminal sterilization of an aqueous suspension is not straightforward because insoluble particles can agglomerate during autoclaving; aseptic processing or dry heat sterilization of the drug substance followed by sterile vehicle addition is normally evaluated. The use of clopidol by injection is therefore considered a non-standard formulation exercise, and no claim of clinical equivalence to feed-administered clopidol can be made without target-animal residue studies conducted under OECD principles.

When Premix Homogeneity Limits Require Carrier Optimization

Premix production for use in medicated feed requires management of segregation, dusting, and moisture-triggered caking. Clopidol active powder is first combined with a small portion of a compatible carrier, often calcium carbonate or lactose, at a ratio not less than 1:9 w/w, then passed through a 600 µm screen before introduction to a double-ribbon blender or paddle mixer. Mixer load should not exceed 70% of nominal working volume, and mixing time is established by sampling from at least 10 points at three bed depths. Finished premix homogeneity should meet an in-process coefficient of variation not more than 5.0% before release. Dust control is necessary because respirable API dust can create handling exposure; containment is addressed by local exhaust ventilation and total enclosed transfer. If the premix contains clopidol titers above 250 g/kg, electrostatic attraction can cause wall sticking in low-humidity conditions, and relative humidity above 60% can induce particle caking; therefore, storage at controlled room temperature with desiccant is specified. The resulting premix is used to provide 125 to 250 mg clopidol per kg of complete poultry feed; the exact dose is determined by the regional marketing authorization and target species. Verification of clopidol content in feed is performed by HPLC following extraction into acidified aqueous methanol, with ultraviolet detection after chromatographic separation.

Formulators should observe that clopidol is not generally positioned as an individual-animal therapeutic. Its primary approved use pattern in poultry is prophylactic administration through medicated feed for group-level control of susceptible Eimeria species. When secondary dosage forms such as tablets, capsules, or oral solutions are manufactured, the dose, dosing interval, and target-species residue depletion profile must be derived from the authorized registered product. Avoid combination with strongly alkaline excipients in solid and solution formulations, because ionization of the phenolic hydroxyl group can alter solubility, dissolution, and chemical stability. Avoid wet granulation with neutral aqueous binders at high drug loading unless pH is controlled and binder distribution is verified by in-process sampling. For food-producing birds, use is not permitted in all production classes; restrictions on laying hens producing eggs for human consumption vary by jurisdiction and must be verified against the regional authorization. Maximum residue limits and withdrawal periods for clopidol are jurisdiction-specific and cannot be transferred from one market to another without explicit regulatory review.